8-K: Limitless X Holdings Amends Manufacturing Agreement to Include Key Nootropic Products

Limitless X Holdings Inc. has amended its manufacturing and distributorship license agreement with LPI to include specific nootropic products and future developments under the existing terms.

Summary

• Limitless X Holdings Inc. has entered into a second amendment to its Manufacturing and Distributorship License Agreement with LPI on May 20, 2025.
• The amendment includes NZT-48 Lions Mane, NZT-48 For Her, and the OneShot Nootropic Pre-Workout under the original agreement, effective September 1, 2023.
• Future products developed by LPI with the terms NZT or OneShot will also be subject to the original agreement.
• Termination agreements from November 1, 2023, do not apply to NZT-48 or related products.
• All other terms of the original license agreement and its first amendment remain in effect.

Sentiment

Score: 7

Explanation: The amendment clarifies an existing agreement and includes future products, which is generally positive. However, the related-party nature of the agreement introduces a potential risk.

Positives

• The amendment clarifies the scope of the original agreement, providing certainty for both Limitless X and LPI regarding key products.
• Inclusion of future products with 'NZT' or 'OneShot' could lead to expanded revenue streams for Limitless X.
• The agreement solidifies the relationship between Limitless X and LPI, ensuring continued manufacturing and distribution of important products.

Risks

• LPI is wholly-owned by Jaspreet Mathur, the Company's CEO, Chairman and significant shareholder, which could present potential conflicts of interest.
• The success of the agreement depends on the continued demand for NZT-48 and related products.

Future Outlook

The agreement ensures that future products developed by LPI with the terms NZT or OneShot will also be subject to the original agreement, potentially expanding the product line and revenue streams for Limitless X.

Management Comments

• The purpose of the Amendment is to memorialize the oral understanding and past practices of the parties regarding the Original Agreement's application to certain products.

Industry Context

The nootropics market is experiencing growth, and this agreement positions Limitless X to capitalize on this trend with its NZT-48 and OneShot product lines.

Related Party Transactions

• LPI is wholly-owned by Jaspreet Mathur, the Company's CEO, Chairman and significant shareholder.

Stakeholder Impact

• Shareholders may benefit from the clarified agreement and potential for increased revenue from included products.
• The agreement ensures continued manufacturing and distribution of key products.

Key Dates

Keywords

Manufacturing and Distributorship License Agreement, Limitless X Holdings, LPI, NZT-48, Nootropic, Amendment